Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer
Keyword(s):
2011 ◽
Keyword(s):
Keyword(s):
2005 ◽
Vol 3
(2)
◽
pp. 77-78
◽
Keyword(s):
2014 ◽
Keyword(s):
2006 ◽
Vol 94
(9)
◽
pp. 1233-1236
◽
Keyword(s):
Keyword(s):
Keyword(s):
2013 ◽
Keyword(s):